Schering To Market Loratadine Metabolite As Aerius In Europe
Executive Summary
Schering-Plough has decided on Aerius as the primary European brand name for desloratadine.
You may also be interested in...
Schering-Plough Targets Annual Rate Of 10 Preclinical Compounds By 2005
Schering-Plough expects to move 10 compounds from discovery into preclinical development each year by 2005.
Schering Desloratadine Onset Of Action Is 1-2 Hours - EU Review Document
Schering-Plough's clinical data for desloratadine supports a one-to-two hour onset of action claim for the antihistamine, the European Public Assessment Report states.
Schering Desloratadine Onset Of Action Is 1-2 Hours - EU Review Document
Schering-Plough's clinical data for desloratadine supports a one-to-two hour onset of action claim for the antihistamine, the European Public Assessment Report states.